Neovasc Announces Participation in Noble Capital Markets Virtual Road Show Series

VANCOUVER and MINNEAPOLIS – (NewMediaWire) – December 01, 2020 – Neovasc, Inc. (“Neovasc”
or the “Company”) (NASDAQ, TSX: NVCN), today
announced their participation in Noble Capital Markets’ Virtual Road Show
Series, presented by Channelchek, scheduled for December 8, 2020.

The virtual road show will
feature a corporate presentation from Neovasc President & CEO, Fred Colen,
followed by a Q & A session proctored by Noble Biotechnology Research
Analyst Ahu Demir, Ph.D., featuring questions submitted by the audience.

The live broadcast of the virtual road show is
scheduled for December 8, 2020, at 1 PM EST.  Registration is free, but
limited to 100.  Register Here.

About
Neovasc Inc.

Neovasc is a specialty medical device company
that develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include Reducer, for the treatment of
refractory angina, which is not currently commercially available in the United
States and has been commercially available in Europe since 2015, and Tiara, for
the transcatheter treatment of mitral valve disease, which is currently under
clinical investigation in the United States, Canada, Israel and Europe. For more
information, visit: www.neovasc.com.

About
Noble Capital Markets

Noble Capital Markets, Inc. was incorporated
in 1984 as a full-service SEC / FINRA registered broker-dealer, dedicated
exclusively to serving underfollowed small / microcap companies through
investment banking, wealth management, trading & execution, and equity
research activities. Over the past 36 years, Noble has raised billions of
dollars for these companies and published more than 45,000 equity research
reports. www.noblecapitalmarkets.com email: contact@noblecapitalmarkets.com

About
Channelchek

Channelchek (.com) is a comprehensive
investor-centric portal – featuring more than 6,000 emerging growth companies -
that provides advanced market data, independent research, balanced news, video
webcasts, exclusive c-suite interviews, and access to virtual road shows. The
site is available to the public at every level without cost or obligation.
Research on Channelchek is provided by Noble Capital Markets, Inc., an SEC /
FINRA registered broker-dealer since 1984. www.channelchek.com email: contact@channelchek.com

Investors

Mike Cavanaugh

Westwicke/ICR

Phone: +1.646.877.9641

Mike.Cavanaugh@westwicke.com

Media

Sean Leous

Westwicke/ICR

Phone: +1.646.677.1839

Sean.Leous@icrinc.com

Forward-Looking Statement
Disclaimer

Certain statements in this news release
contain forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and applicable Canadian securities
laws that may not be based on historical fact.  When used herein, the
words “expect”, “anticipate”, “estimate”,
“may”, “will”, “should”, “intend,”
“believe”, and similar expressions, are intended to identify
forward-looking statements. Forward-looking statements may involve, but are not
limited to, the expected impact on Reducer revenue generation during the fourth
quarter, the Company’s ability to build on progress and optimizing the value of
its devices, the likelihood of approval under the FDA’s decision on the PMA,
the expansion of its product range, prospects for regulatory approvals and the
growing cardiovascular marketplace. Forward-looking statements are based on
estimates and assumptions made by the Company in light of its experience and
its perception of historical trends, current conditions and expected future
developments, as well as other factors that the Company believes are
appropriate in the circumstances. Many factors could cause the Company’s actual
results, performance or achievements to differ materially from those expressed
or implied by the forward-looking statements, including those described in the
“Risk Factors” section of the Company’s Annual Report on Form 20-F
and in the Management’s Discussion and Analysis for the three and nine months
ended September 30, 2020 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be
considered carefully, and readers should not place undue reliance on the
Company’s forward-looking statements. The Company has no intention and
undertakes no obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.